Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Crinetics Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics to Highlight Broad Pipeline at ENDO 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CRNX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.